share_log

Intelligent Bio Solutions | UPLOAD: Others

SEC announcement ·  Mar 13 13:08
Summary by Moomoo AI
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 4, 2024, will not undergo review by the commission. The SEC's communication, dated March 13, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Benjamin Richie at the SEC is the point of contact for any further inquiries from the company.
Intelligent Bio Solutions Inc., a company listed in the United States, has been informed by the Securities and Exchange Commission (SEC) that its Registration Statement on Form S-3, filed on March 4, 2024, will not undergo review by the commission. The SEC's communication, dated March 13, 2024, was addressed to Harry Simeonidis, the Chief Executive Officer of Intelligent Bio Solutions. The SEC's letter reminded the company and its management of their responsibility for the accuracy and adequacy of their disclosures, irrespective of the SEC's review process. The SEC also referenced Rules 460 and 461, which pertain to requests for acceleration of the registration process. Benjamin Richie at the SEC is the point of contact for any further inquiries from the company.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more